levofloxacin has been researched along with Critical Illness in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (78.95) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| He, X; Jian, L; Li, X; Zhao, L | 1 |
| Mueller, BA; Shaw, AR | 1 |
| Cojutti, P; Cotta, MO; Della Rocca, G; Lugano, M; Pea, F; Roberts, JA | 1 |
| Al-Hasan, MN; Ereshefsky, BJ; Gokun, Y; Martin, CA | 1 |
| Alvarez Lerma, F; Borges Sá, M; Gracia Arnillas, MP; Grau Cerrato, S; Morón Jiménez, A; Ortiz López, R; Romero Luján, JL | 1 |
| Abraham, E; Fish, DN; Rebuck, JA | 1 |
| Baldassarre, M; Brollo, L; Cusenza, A; Di Qual, E; Furlanut, M; Pea, F | 1 |
| Baldassarre, M; Brollo, L; Di Qual, E; Furlanut, M; Nascimben, E; Pavan, F; Pea, F | 1 |
| Furlanut, M; Pea, F | 1 |
| Alvarez Lerma, F | 1 |
| Cristini, F; Scudeller, L; Viale, P | 1 |
| Alvarez-Lerma, F; Bermejo, B; León, C; Olaechea, P; Palomar, M; Sanchez, M | 1 |
| Barth, J; Hochhaus, G; Jäger, D; Kaufmann, S; Tayab, ZR | 1 |
| Benko, R; Doro, P; Gardi, J; Hajdu, E; Matuz, M; Molnar, A; Nagy, E; Peto, Z; Soos, G | 1 |
| Czock, D; de Groot, K; Fliser, D; Hafer, C; Haller, H; Hüsig-Linde, C; Keller, F; Kielstein, JT; Kuse, E; Langhoff, A; Schöpke, T; Swoboda, S | 1 |
| Bucher, M; Hansen, E; Jakob, W; Kees, F; Lemberger, P | 1 |
| Abraham, E; Fish, DN; Malone, RS; Teitelbaum, I | 1 |
| Boos, C; Bruch, HP; Guenter, SG; Iven, H; Muhl, E | 1 |
| Bellmann, R; Bellmann-Weiler, R; Dunzendorfer, S; Egger, P; Gritsch, W; Joannidis, M; Wiedermann, CJ | 1 |
2 review(s) available for levofloxacin and Critical Illness
| Article | Year |
|---|---|
Antibiotic Dosing in Continuous Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Computer Simulation; Critical Illness; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Renal Replacement Therapy; Sepsis; Tazobactam; Thienamycins | 2017 |
Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients.
Topics: Administration, Oral; Anti-Infective Agents; Area Under Curve; Biological Availability; Case-Control Studies; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Maximum Tolerated Dose; Ofloxacin; Pneumonia, Bacterial; Reference Values; Respiratory Tract Infections | 2004 |
6 trial(s) available for levofloxacin and Critical Illness
| Article | Year |
|---|---|
Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Area Under Curve; Creatinine; Critical Illness; Female; Half-Life; Humans; Injections, Intravenous; Intensive Care Units; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Time Factors | 2002 |
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.
Topics: Aged; Anti-Infective Agents; Chromatography, High Pressure Liquid; Critical Illness; Cross Infection; Female; Humans; Injections, Intravenous; Intensive Care Units; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Time Factors; Ventilators, Mechanical | 2003 |
Clinical experience with levofloxacin in the treatment of pneumonia in ICU patients.
Topics: Anti-Infective Agents; Confidence Intervals; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospital Mortality; Humans; Infusions, Intravenous; Intensive Care Units; Levofloxacin; Male; Microbial Sensitivity Tests; Odds Ratio; Ofloxacin; Pneumonia, Bacterial; Prognosis; Risk Assessment; Spain; Treatment Outcome | 2004 |
Levofloxacin in the treatment of pneumonia in intensive care unit patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Critical Illness; Cross Infection; Drug Administration Schedule; Female; Humans; Intensive Care Units; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Treatment Outcome | 2004 |
Do intensive care patients need an individualized dosing regimen for levofloxacin?
Topics: Anti-Bacterial Agents; Critical Illness; Female; Humans; Intensive Care Units; Levofloxacin; Male; Middle Aged; Models, Biological; Ofloxacin; Pancreatitis; Pneumonia, Bacterial; Sepsis | 2006 |
Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients.
Topics: Acute Kidney Injury; Aged; Anti-Infective Agents; Area Under Curve; Chromatography, High Pressure Liquid; Critical Illness; Female; Half-Life; Hemodiafiltration; Hemofiltration; Humans; Levofloxacin; Male; Metabolic Clearance Rate; Middle Aged; Ofloxacin | 2002 |
11 other study(ies) available for levofloxacin and Critical Illness
| Article | Year |
|---|---|
Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients.
Topics: Anti-Bacterial Agents; Ceftazidime; Critical Illness; Drug Combinations; Drug Resistance, Bacterial; Humans; Kidney Diseases; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Pseudomonas aeruginosa; Pseudomonas Infections | 2020 |
Does Critical Illness Change Levofloxacin Pharmacokinetics?
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Critical Illness; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Models, Theoretical; Monte Carlo Method; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections | 2015 |
Comparison of ß-lactam plus aminoglycoside versus ß-lactam plus fluoroquinolone empirical therapy in serious nosocomial infections due to Gram-negative bacilli.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Critical Illness; Cross Infection; Drug Therapy, Combination; Female; Fluoroquinolones; Gentamicins; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Proportional Hazards Models; Retrospective Studies; Tobramycin; Treatment Outcome | 2017 |
[Levofloxacin in the treatment of nosocomial infection in critically ill patients].
Topics: Anti-Bacterial Agents; Critical Illness; Cross Infection; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Retrospective Studies | 2008 |
Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia.
Topics: Adult; Aged; Biological Availability; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Intensive Care Units; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Probability; Respiration, Artificial; Risk Assessment; Sampling Studies; Sensitivity and Specificity; Treatment Outcome | 2003 |
Levofloxacin: a suitable option for the infectious disease consultant.
Topics: Anti-Bacterial Agents; Communicable Diseases; Critical Illness; Cross Infection; Humans; Intensive Care Units; Levofloxacin; Ofloxacin; Referral and Consultation; Sensitivity and Specificity | 2004 |
Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Critical Illness; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Ventilator-Associated; Prospective Studies | 2007 |
Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Anuria; Aza Compounds; Critical Care; Critical Illness; Female; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Male; Metabolic Clearance Rate; Middle Aged; Moxifloxacin; Multiple Organ Failure; Ofloxacin; Quinolines; Renal Dialysis; Sepsis | 2006 |
Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anti-Infective Agents; Area Under Curve; Chromatography, High Pressure Liquid; Critical Illness; Female; Hemofiltration; Humans; Intensive Care Units; Levofloxacin; Male; Middle Aged; Ofloxacin; Statistics, Nonparametric | 2001 |
Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Critical Illness; Female; Hemofiltration; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Renal Insufficiency; Renal Replacement Therapy | 2001 |
Elimination of levofloxacin in critically ill patients with renal failure: influence of continuous veno-venous hemofiltration.
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Critical Illness; Female; Hemofiltration; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Renal Insufficiency | 2002 |